Biological Biomarkers of Response and Resistance to Immune Checkpoint Inhibitors in Renal Cell Carcinoma

SIMPLE SUMMARY: A several immunotherapy-based combinations regimen improved overall survival, and became the new first-line standard of care for metastatic clear cell renal cell carcinoma (mccRCC) patients. However, a subset of patients, approximatively 30 to 60%, are refractory to these therapies o...

Descripción completa

Detalles Bibliográficos
Autores principales: Masson, Claire, Thouvenin, Jonathan, Boudier, Philippe, Maillet, Denis, Kuchler-Bopp, Sabine, Barthélémy, Philippe, Massfelder, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296643/
https://www.ncbi.nlm.nih.gov/pubmed/37370768
http://dx.doi.org/10.3390/cancers15123159

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296643/
https://www.ncbi.nlm.nih.gov/pubmed/37370768
http://dx.doi.org/10.3390/cancers15123159

Ejemplares similares